The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta‐Analysis

• Published in: Obesity (Silver Spring, Md.) Vol. 26; no. 1; pp. 70 - 80
• Main Authors: Cai, Xiaoling, Yang, Wenjia, Gao, Xueying, Chen, Yifei, Zhou, Lingli, Zhang, Simin, Han, Xueyao, Ji, Linong
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.01.2018
• Subjects: Bias; Diabetes; Drug dosages; Glucose; Insulin resistance; Meta-analysis; Sodium; Statistical analysis; Studies; Weight control
• ISSN: 1930-7381; 1930-739X
• DOI: 10.1002/oby.22066

Objective Sodium glucose cotransporter 2 (SGLT2) inhibitors may induce urinary glucose excretion via the inhibition of renal glucose reabsorption, improve glycemic control, and lower body weight. The aim of this meta‐analysis was to evaluate weight changes in patients who received different dosages of SGLT2 inhibitors. Methods Overall, 55 placebo‐controlled trials were included. Results The results indicated that treatment with 2.5 mg, 5 mg, 10 mg, and 20 mg of dapagliflozin led to significant decreases in body weight compared with a placebo (weighted mean difference [WMD], −1.30 kg, −1.51 kg, −1.79 kg, −2.24 kg, respectively; P < 0.001). Treatment with 50 mg, 100 mg, 200 mg, and 300 mg of canagliflozin also led to significant decreases in weight (WMD, −1.20 kg, −1.82 kg, −1.83 kg, −2.37 kg, respectively; P < 0.001). In the treatment with empagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin, body weight also significantly decreased. The decrease in weight was associated with the dosage of dapagliflozin (P < 0.05). Conclusions Body weight significantly decreased in patients with type 2 diabetes who received different dosages of SGLT2 inhibitors compared with patients who received a placebo. Moreover, in patients treated with dapagliflozin, there was a statistically significant dosage‐dependent trend in body weight reduction.